LAROSA JOSEPH J 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jun 25, 2024
Insider Transaction Report
Form 4
LAROSA JOSEPH J
SVP Gen Counsel and Secretary
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-06-24−14,450→ 14,450 totalExercise: $555.67Exp: 2025-12-16→ Common Stock (14,450 underlying) - Tax Payment
Common Stock
2024-06-24$1060.13/sh−11,084$11,750,481→ 39,803 total - Exercise/Conversion
Common Stock
2024-06-24$555.67/sh+14,450$8,029,431→ 50,887 total
Holdings
- 371(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.